Document:

EX-10.2

 Exhibit 10.2 
 The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, of the United States of America (the “Act”) or the securities laws of any
state (“State”) of the United States of America and may not be sold, transferred, pledged, hypothecated or distributed, directly or indirectly, to a U.S. person (as defined in Regulation S adopted by the U.S. Securities and Exchange
Commission under the Act) or within the United States unless such securities are (i) registered under the Act and any applicable State securities act (a “State Act”), or (ii) exempt from registration under the Act and any
applicable State Act and the Company has received an opinion of counsel to such effect reasonably satisfactory to it, or (iii) sold in accordance with Regulation S and the Company has received an opinion of counsel to such effect reasonably
satisfactory to it. 
 SOPHIRIS BIO INC. 
 STOCK OPTION PLAN – OPTION CERTIFICATE 
 This Option Certificate is issued pursuant to
the provisions of the Stock Option Plan (the “Plan”) of Sophiris Bio Inc. (the “Company”) and evidences that (First Name/Last Name) is the holder (the “Option Holder”) of an option (the “Option”) to purchase
up to             common shares (the “Shares”) in the capital stock of the Company at a purchase price of Cdn. $0.00 per Share (the “Exercise Price”). This Option may be
exercised at any time and from time to time, subject to the terms and conditions of the attached vesting schedule, from and including the following Grant Date through to and including up to 5:00 p.m. local time in Vancouver, British Columbia (the
“Expiry Time”) on the following Expiry Date: 
  

	(a)	the Grant Date of this Option is                     ; and

  

	(b)	subject to sections 5.4, 6.2, 6.3, 6.4 or 11.3 of the Plan, the Expiry Date of this Option is
                     

To exercise this Option, the Option Holder must deliver to the Administrator of the Plan, prior to the Expiry Time on the Expiry Date, an Exercise
Notice, in the form provided in the Plan, which is incorporated by reference herein, together with the original of this Option Certificate and a certified cheque or bank draft payable to the Company in an amount equal to the aggregate of the
Exercise Price of the Shares in respect of which this Option is being exercised. 
 This Option Certificate and the Option evidenced hereby is
not assignable, transferable or negotiable and is subject to the detailed terms and conditions contained in the Plan. This Option Certificate is issued for convenience only and in the case of any dispute with regard to any matter in respect hereof,
the provisions of the Plan and the records of the Company shall prevail. This Option is also subject to the terms and conditions contained in the schedules, if any, attached hereto. 
 If the Option Holder is a resident or citizen of the United States of America at the time of the exercise of the Option, the certificate(s) representing the Shares will be endorsed with the following or a
similar legend: 
 “The securities represented by this certificate have not been registered under the Securities Act of
1933, as amended, of the United States of America (the “Act”) or the securities laws of any state (“State”) of the United States of America and 

 
may not be sold, transferred, pledged, hypothecated or distributed, directly or indirectly, to a U.S. person (as defined in Regulation S adopted by the U.S. Securities and Exchange Commission
under the Act) or within the United States unless such securities are (i) registered under the Act and any applicable State securities act (a “State Act”), or (ii) exempt from registration under the Act and any applicable State
Act and the Company has received an opinion of counsel to such effect reasonably satisfactory to it, or (iii) sold in accordance with Regulation S and the Company has received an opinion of counsel to such effect reasonably satisfactory to
it.” 
 Capitalized terms appearing herein unless otherwise defined herein have their respective meanings in the Plan. 

Sophiris Bio Inc. 
 Per: 

 

	
	                             
                                         
 
	 Authorized Signatory

 The Option Holder acknowledges receipt of a copy of the Plan and represents to the Company that the Option Holder is
familiar with the terms and conditions of the Plan, and hereby accepts this Option subject to all of the terms and conditions of the Plan. The Option Holder agrees to execute, deliver, file and otherwise assist the Company in filing any report,
undertaking or document with respect to the awarding of the Option and exercise of the Option, as may be required by the Regulatory Authorities. The Option Holder further acknowledges that if the Plan has not been approved by the shareholders of the
Company on the Grant Date, this Option is not exercisable until such approval has been obtained. 
  

			
	
                        
                                         
      
	  	                             
                                      
	 Signature of Option Holder
	  	Date Signed
		
	
                        
                                         
      
	  	
	 Print Name of Option Holder
	  	
		
	
                        
                                         
      
	  	
		
	
                        
                                         
      
	  	
		
	
                        
                                         
      
	  	
	 Address
	  	

  
 A-2

 OPTION CERTIFICATE – SCHEDULE 

The additional terms and conditions attached to the Option represented by this Option Certificate are as follows: 

The Options will not be exercisable unless and until they have vested and then only to the extent that they have vested. The Options will vest in
accordance with the following: 
  

	(a)	             Options will vest and be exercisable on or after
            ; 

  

	(b)	             additional Options will vest and be exercisable on or after
            ; 

  

	(c)	             additional Options will vest and be exercisable on or after
            ; and 

 Under the Plan, this Option is:

     X      an incentive stock option (“ISO”); or 

             a non-qualified option (“NQO”). 

 SOPHIRIS BIO INC. 

STOCK OPTION PLAN 
 NOTICE OF EXERCISE OF OPTION 
  

			
	 TO:    
	  	The Administrator, Stock Option Plan
		  	Sophiris Bio Inc.
		  	1258 Prospect Street
		  	San Diego, CA 92037
		  	(or such other address as the Company may advise)

 The undersigned hereby irrevocably gives notice, pursuant to the Stock Option Plan (the “Plan”) of Sophiris Bio
Inc. (the “Company”), of the exercise of the Option to acquire and hereby subscribes for (cross out inapplicable item): 
  

	(a)	all of the Shares; or 

  

	(b)	             of the Shares; 

 which are the subject of the Option Certificate attached hereto (attach your original Option Certificate). 
 The undersigned tenders herewith a certified cheque or bank draft (circle one) payable to “Sophiris Bio Inc.” in an amount equal to the aggregate Exercise Price of the aforesaid Shares
and directs the Company to issue the certificate evidencing said Shares in the name of the undersigned to be mailed to the undersigned at the following address (provide full complete address): 

 

					
		 	  
	 	
			
		 	  
	 	
			
		 	  
	 	
			
		 	  
	 	

 The undersigned acknowledges the Option is not validly exercised unless this Notice is completed in strict compliance
with this form and delivered to the required address with the required payment prior to 5:00 p.m. local time in Vancouver, B.C. on the Expiry Date of the Option. 
  

					
	 DATED the      day of
                     , 20    
	  		 	
		  	Signature of Option HolderEX-10.3

 Exhibit 10.3 

PROTOX THERAPEUTICS INC. 
 1500 – 885 West Georgia Street 
 Vancouver, British Columbia, Canada, V6C 3E8

 July 15, 2011 
 Oxford Finance LLC 
 133 North Fairfax Street 

Alexandria, VA 22314 
 Attn: Vice President and
General Counsel 
 Ladies and Gentlemen: 
 For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by PROTOX THERAPEUTICS INC., a corporation amalgamated under the Business Corporations Act (British
Columbia) (the “Company”), the Company hereby grants to OXFORD FINANCE LLC and/or its affiliates (collectively, the “Lender”) the right to purchase up to USD $1,000,000 in the aggregate (or up to the CDN dollar equivalent thereof
on the date of exercise) of Qualified Financing Securities (as defined below) in one or more Qualified Financings (as defined below), subject to regulatory approval. Lender shall not have any obligation to purchase Qualified Financing Securities in
any Qualified Financing. Any Lender purchaser of Qualified Financing Securities shall be an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Act”). 

As used herein: 

“Qualified Financing” means the sale and issuance by the Company after the date hereof, in a single transaction or series of
related transactions, of common shares in its capital, and/or of instruments or securities convertible into or exercisable or exchangeable for common shares in its capital, to one or more investors, in a private sale, for cash for financing
purposes. 
 “Qualified Financing Securities” means, with respect to any Qualified Financing, the class and/or series
of shares, and/or the instruments or other securities, sold and/or issued by the Company in such Qualified Financing. 
 The
purchase, if any, by Lender of Qualified Financing Securities in any Qualified Financing shall be made, subject to the provisions of this letter, upon the same terms and conditions (including, without limitation, price) as the purchases by the other
purchasers of Qualified Financing Securities in such Qualified Financing, and each Lender purchaser shall execute the definitive stock purchase agreement, investor rights agreement and other agreements

 
(collectively, “Operative Documents”) executed by such other purchasers in connection with such Qualified Financing. 

The Company shall give Lender not less than twenty (20) days written notice prior to the closing of each Qualified Financing, which
notice shall state the principal terms (including, without limitation, the principal investors) of such Qualified Financing, and shall provide such drafts and definitive copies of the Operative Documents and other documents and information in
connection with such Qualified Financing as are provided to the non-Lender purchasers in such Qualified Financing. Lender may exercise its purchase rights hereunder with respect to a Qualified Financing by delivering written notice thereof to the
Company no less than five (5) days prior to such closing. 

  
 2 

 The rights of Lender to Purchase Qualified Financing Securities in Qualified Financings as
set forth above shall survive through October 15, 2014. 
  

			
	Very truly yours,
	
	PROTOX THERAPEUTICS INC.
		
	By:	 	/s/ Allison Hulme
	Name:	 	Allison Hulme
	Title:	 	Chief Operating Officer

  

			
	ACCEPTED AND AGREED:
	
	OXFORD FINANCE LLC
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 3 

 The rights of Lender to Purchase Qualified Financing Securities in Qualified Financings as
set forth above shall survive through October 15, 2014. 
  

			
	Very truly yours,
	
	PROTOX THERAPEUTICS INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

			
	ACCEPTED AND AGREED:
	
	OXFORD FINANCE LLC
		
	By:	 	/s/ T. A. Lex
	Name:	 	T. A. Lex
	Title:	 	COO

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]